
Sign up to save your podcasts
Or


Novo Nordisk can't keep up with demand for Ozempic and Wegovy, giving competitor Eli Lilly the edge in the GLP-1 market. And off-brand competitors continue to hammer the company's market position. Layoffs and board resignations signal that Novo Nordisk has entered a downward spiral. But with new leaders, acquisitions and deals, can they force a comeback?
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
By Wondery4.6
1253412,534 ratings
Novo Nordisk can't keep up with demand for Ozempic and Wegovy, giving competitor Eli Lilly the edge in the GLP-1 market. And off-brand competitors continue to hammer the company's market position. Layoffs and board resignations signal that Novo Nordisk has entered a downward spiral. But with new leaders, acquisitions and deals, can they force a comeback?
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

10,425 Listeners

30,223 Listeners

773 Listeners

466 Listeners

19,274 Listeners

4,142 Listeners

4,059 Listeners

2,164 Listeners

19,063 Listeners

2,158 Listeners

3,048 Listeners

22,966 Listeners

1,483 Listeners

7,813 Listeners

255 Listeners

2,474 Listeners

253 Listeners

2,119 Listeners

7,386 Listeners

860 Listeners

1,530 Listeners

396 Listeners

231 Listeners

391 Listeners

574 Listeners

69 Listeners

539 Listeners

871 Listeners

203 Listeners